FRAX®: Prediction of major osteoporotic fractures in women from the general population: The OPUS study

Karine Briot (Corresponding Author), Simon Paternotte, Sami Kolta, Richard Eastell, Dieter Felsenberg, David M. Reid, Claus C. Glüer, Christian Roux

Research output: Contribution to journalArticle

21 Citations (Scopus)
4 Downloads (Pure)

Abstract

Purposes: The aim of this study was to analyse how well FRAX® predicts the risk of major osteoporotic and vertebral fractures over 6 years in postmenopausal women from general population. 

Patients and methods: The OPUS study was conducted in European women aged above 55 years, recruited in 5 centers from random population samples and followed over 6 years. The population for this study consisted of 1748 women (mean age 74.2 years) with information on incident fractures. 742 (43.1%) had a prevalent fracture; 769 (44%) and 155 (8.9%) of them received an antiosteoporotic treatment before and during the study respectively. We compared FRAX® performance with and without bone mineral density (BMD) using receiver operator characteristic (ROC) c-statistical analysis with ORs and areas under receiver operating characteristics curves (AUCs) and net reclassification improvement (NRI). 

Results: 85 (4.9%) patients had incident major fractures over 6 years. FRAX® with and without BMD predicted these fractures with an AUC of 0.66 and 0.62 respectively. The AUC were 0.60, 0.66, 0.69 for history of low trauma fracture alone, age and femoral neck (FN) BMD and combination of the 3 clinical risk factors, respectively. FRAX® with and without BMD predicted incident radiographic vertebral fracture (n = 65) with an AUC of 0.67 and 0.65 respectively. NRI analysis showed a significant improvement in risk assignment when BMD is added to FRAX®. 

Conclusions: This study shows that FRAX® with BMD and to a lesser extent also without FN BMD predict major osteoporotic and vertebral fractures in the general population.

Original languageEnglish
Article numbere83436
Pages (from-to)1-10
Number of pages10
JournalPloS ONE
Volume8
Issue number12
DOIs
Publication statusPublished - 30 Dec 2013

Fingerprint

Osteoporotic Fractures
bone density
Bone Density
Minerals
Bone
prediction
Area Under Curve
Population
Femur Neck
thighs
taxonomic revisions
ROC Curve
risk factors
statistical analysis
Mathematical operators
Statistical methods
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Briot, K., Paternotte, S., Kolta, S., Eastell, R., Felsenberg, D., Reid, D. M., ... Roux, C. (2013). FRAX®: Prediction of major osteoporotic fractures in women from the general population: The OPUS study. PloS ONE, 8(12), 1-10. [e83436]. https://doi.org/10.1371/journal.pone.0083436

FRAX® : Prediction of major osteoporotic fractures in women from the general population: The OPUS study. / Briot, Karine (Corresponding Author); Paternotte, Simon; Kolta, Sami; Eastell, Richard; Felsenberg, Dieter; Reid, David M.; Glüer, Claus C.; Roux, Christian.

In: PloS ONE, Vol. 8, No. 12, e83436, 30.12.2013, p. 1-10.

Research output: Contribution to journalArticle

Briot, K, Paternotte, S, Kolta, S, Eastell, R, Felsenberg, D, Reid, DM, Glüer, CC & Roux, C 2013, 'FRAX®: Prediction of major osteoporotic fractures in women from the general population: The OPUS study', PloS ONE, vol. 8, no. 12, e83436, pp. 1-10. https://doi.org/10.1371/journal.pone.0083436
Briot K, Paternotte S, Kolta S, Eastell R, Felsenberg D, Reid DM et al. FRAX®: Prediction of major osteoporotic fractures in women from the general population: The OPUS study. PloS ONE. 2013 Dec 30;8(12):1-10. e83436. https://doi.org/10.1371/journal.pone.0083436
Briot, Karine ; Paternotte, Simon ; Kolta, Sami ; Eastell, Richard ; Felsenberg, Dieter ; Reid, David M. ; Glüer, Claus C. ; Roux, Christian. / FRAX® : Prediction of major osteoporotic fractures in women from the general population: The OPUS study. In: PloS ONE. 2013 ; Vol. 8, No. 12. pp. 1-10.
@article{12c394b14ca14967b8a820e23193ca9e,
title = "FRAX{\circledR}: Prediction of major osteoporotic fractures in women from the general population: The OPUS study",
abstract = "Purposes: The aim of this study was to analyse how well FRAX{\circledR} predicts the risk of major osteoporotic and vertebral fractures over 6 years in postmenopausal women from general population. Patients and methods: The OPUS study was conducted in European women aged above 55 years, recruited in 5 centers from random population samples and followed over 6 years. The population for this study consisted of 1748 women (mean age 74.2 years) with information on incident fractures. 742 (43.1{\%}) had a prevalent fracture; 769 (44{\%}) and 155 (8.9{\%}) of them received an antiosteoporotic treatment before and during the study respectively. We compared FRAX{\circledR} performance with and without bone mineral density (BMD) using receiver operator characteristic (ROC) c-statistical analysis with ORs and areas under receiver operating characteristics curves (AUCs) and net reclassification improvement (NRI). Results: 85 (4.9{\%}) patients had incident major fractures over 6 years. FRAX{\circledR} with and without BMD predicted these fractures with an AUC of 0.66 and 0.62 respectively. The AUC were 0.60, 0.66, 0.69 for history of low trauma fracture alone, age and femoral neck (FN) BMD and combination of the 3 clinical risk factors, respectively. FRAX{\circledR} with and without BMD predicted incident radiographic vertebral fracture (n = 65) with an AUC of 0.67 and 0.65 respectively. NRI analysis showed a significant improvement in risk assignment when BMD is added to FRAX{\circledR}. Conclusions: This study shows that FRAX{\circledR} with BMD and to a lesser extent also without FN BMD predict major osteoporotic and vertebral fractures in the general population.",
author = "Karine Briot and Simon Paternotte and Sami Kolta and Richard Eastell and Dieter Felsenberg and Reid, {David M.} and Gl{\"u}er, {Claus C.} and Christian Roux",
note = "We would like to acknowledge the contributions of the other members of the OPUS teams at the five participating centres: Rosie Reid (deceased), Lana Gibson and Alison Stewart in Aberdeen; Antonia Gerwinn, Dr. Maren Gl{\"u}er, Roswitha John, Roswitha Marunde-Ott, Monika Mohr, Regina Schlenger, Pia Zschoche, Dr Reinhard Barkmann, Dr. Carsten Liess, Carsten Rose and Wolfram Timm in Kiel; Therese Kolta, Nathalie Delfau in Paris; Margaret Paggiosi, Nicky Peel, Diane Shutt, Anne Stapleton, Debbie Swindell in Sheffield. We also would like to thank for the support of the equipment manufacturers: DMS, IGEA, OSI/Osteometer Meditech, Quidel/metra. Funding: The OPUS cohort was sponsored by Eli Lilly, Sanofi-Aventis, Procter and Gamble Pharmaceuticals, Hoffman-La Roche, Pfizer and Novartis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author and coauthors did not receive any funding from these commercial sources.",
year = "2013",
month = "12",
day = "30",
doi = "10.1371/journal.pone.0083436",
language = "English",
volume = "8",
pages = "1--10",
journal = "PloS ONE",
issn = "1932-6203",
publisher = "PUBLIC LIBRARY SCIENCE",
number = "12",

}

TY - JOUR

T1 - FRAX®

T2 - Prediction of major osteoporotic fractures in women from the general population: The OPUS study

AU - Briot, Karine

AU - Paternotte, Simon

AU - Kolta, Sami

AU - Eastell, Richard

AU - Felsenberg, Dieter

AU - Reid, David M.

AU - Glüer, Claus C.

AU - Roux, Christian

N1 - We would like to acknowledge the contributions of the other members of the OPUS teams at the five participating centres: Rosie Reid (deceased), Lana Gibson and Alison Stewart in Aberdeen; Antonia Gerwinn, Dr. Maren Glüer, Roswitha John, Roswitha Marunde-Ott, Monika Mohr, Regina Schlenger, Pia Zschoche, Dr Reinhard Barkmann, Dr. Carsten Liess, Carsten Rose and Wolfram Timm in Kiel; Therese Kolta, Nathalie Delfau in Paris; Margaret Paggiosi, Nicky Peel, Diane Shutt, Anne Stapleton, Debbie Swindell in Sheffield. We also would like to thank for the support of the equipment manufacturers: DMS, IGEA, OSI/Osteometer Meditech, Quidel/metra. Funding: The OPUS cohort was sponsored by Eli Lilly, Sanofi-Aventis, Procter and Gamble Pharmaceuticals, Hoffman-La Roche, Pfizer and Novartis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author and coauthors did not receive any funding from these commercial sources.

PY - 2013/12/30

Y1 - 2013/12/30

N2 - Purposes: The aim of this study was to analyse how well FRAX® predicts the risk of major osteoporotic and vertebral fractures over 6 years in postmenopausal women from general population. Patients and methods: The OPUS study was conducted in European women aged above 55 years, recruited in 5 centers from random population samples and followed over 6 years. The population for this study consisted of 1748 women (mean age 74.2 years) with information on incident fractures. 742 (43.1%) had a prevalent fracture; 769 (44%) and 155 (8.9%) of them received an antiosteoporotic treatment before and during the study respectively. We compared FRAX® performance with and without bone mineral density (BMD) using receiver operator characteristic (ROC) c-statistical analysis with ORs and areas under receiver operating characteristics curves (AUCs) and net reclassification improvement (NRI). Results: 85 (4.9%) patients had incident major fractures over 6 years. FRAX® with and without BMD predicted these fractures with an AUC of 0.66 and 0.62 respectively. The AUC were 0.60, 0.66, 0.69 for history of low trauma fracture alone, age and femoral neck (FN) BMD and combination of the 3 clinical risk factors, respectively. FRAX® with and without BMD predicted incident radiographic vertebral fracture (n = 65) with an AUC of 0.67 and 0.65 respectively. NRI analysis showed a significant improvement in risk assignment when BMD is added to FRAX®. Conclusions: This study shows that FRAX® with BMD and to a lesser extent also without FN BMD predict major osteoporotic and vertebral fractures in the general population.

AB - Purposes: The aim of this study was to analyse how well FRAX® predicts the risk of major osteoporotic and vertebral fractures over 6 years in postmenopausal women from general population. Patients and methods: The OPUS study was conducted in European women aged above 55 years, recruited in 5 centers from random population samples and followed over 6 years. The population for this study consisted of 1748 women (mean age 74.2 years) with information on incident fractures. 742 (43.1%) had a prevalent fracture; 769 (44%) and 155 (8.9%) of them received an antiosteoporotic treatment before and during the study respectively. We compared FRAX® performance with and without bone mineral density (BMD) using receiver operator characteristic (ROC) c-statistical analysis with ORs and areas under receiver operating characteristics curves (AUCs) and net reclassification improvement (NRI). Results: 85 (4.9%) patients had incident major fractures over 6 years. FRAX® with and without BMD predicted these fractures with an AUC of 0.66 and 0.62 respectively. The AUC were 0.60, 0.66, 0.69 for history of low trauma fracture alone, age and femoral neck (FN) BMD and combination of the 3 clinical risk factors, respectively. FRAX® with and without BMD predicted incident radiographic vertebral fracture (n = 65) with an AUC of 0.67 and 0.65 respectively. NRI analysis showed a significant improvement in risk assignment when BMD is added to FRAX®. Conclusions: This study shows that FRAX® with BMD and to a lesser extent also without FN BMD predict major osteoporotic and vertebral fractures in the general population.

UR - http://www.scopus.com/inward/record.url?scp=84893621370&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0083436

DO - 10.1371/journal.pone.0083436

M3 - Article

C2 - 24386199

AN - SCOPUS:84893621370

VL - 8

SP - 1

EP - 10

JO - PloS ONE

JF - PloS ONE

SN - 1932-6203

IS - 12

M1 - e83436

ER -